These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 38614267)

  • 1. Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors.
    Fan J; Zhu J; Zhu H; Xu H
    Crit Rev Oncol Hematol; 2024 Jun; 198():104362. PubMed ID: 38614267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
    Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
    Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
    Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
    Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
    Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies.
    Moehler M; Göpfert K; Lenz HJ
    Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
    Good L; Benner B; Carson WE
    Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
    Erin N; Grahovac J; Brozovic A; Efferth T
    Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of TAMs in the Regulation of Tumor Cell Resistance to Chemotherapy.
    McWhorter R; Bonavida B
    Crit Rev Oncog; 2024; 29(4):97-125. PubMed ID: 38989740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.
    Kundu M; Butti R; Panda VK; Malhotra D; Das S; Mitra T; Kapse P; Gosavi SW; Kundu GC
    Mol Cancer; 2024 May; 23(1):92. PubMed ID: 38715072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid suppressor cells in cancer and autoimmunity.
    Sica A; Massarotti M
    J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Nanoimmunotherapy by Modulating Tumor-Associated Macrophages for Cancer Therapy.
    Hao J; Zhao X; Wang C; Cao X; Liu Y
    Bioconjug Chem; 2024 Jul; 35(7):867-882. PubMed ID: 38919067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
    Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
    Front Immunol; 2018; 9():2250. PubMed ID: 30349530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer.
    Kemp SB; Pasca di Magliano M; Crawford HC
    Cell Mol Gastroenterol Hepatol; 2021; 12(5):1531-1542. PubMed ID: 34303882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Regulation of Ginsenosides on Myeloid Immunosuppressive Cells in the Tumor Microenvironment.
    Zhang Y; Qiu Z; Qiu Y; Su T; Qu P; Jia A
    Integr Cancer Ther; 2019; 18():1534735419886655. PubMed ID: 31729239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage-based cancer immunotherapy: Challenges and opportunities.
    Bai H; Feng L; Schmid F
    Exp Cell Res; 2024 Sep; 442(1):114198. PubMed ID: 39103071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tumor-associated macrophages as an antitumor strategy.
    Cheng N; Bai X; Shu Y; Ahmad O; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting tumor-associated macrophages to reverse antitumor drug resistance.
    Li S; Sheng J; Zhang D; Qin H
    Aging (Albany NY); 2024 May; 16(11):10165-10196. PubMed ID: 38787372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.